Year: 2006

A Randomized, Double-Blind, Placebo- Controlled, Multicentre Phase III Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for12 weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.

Year: 2006
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General

CONNECT WITH US

CONTACT US

Disclaimer: This website provides general information only; it should not be construed as medical advice nor does it replace the need to seek medical advice from a qualified medical professional. To the maximum extent permitted by law, Genesis Research Services Pty Ltd will not be liable in any way for any injury, loss or damage suffered by you through accessing or using the information on this website. View our Privacy Policy. You are strictly prohibited from downloading, copying, altering, modifying, distributing, adapting, modifying and/or re-transmitting any or all of the content on the website for any commercial use without the written consent of Genesis Research Services.